Drug Approval | September 28, 2024
FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
India has taken the lead in recognising NAFLD as a major non-communicable disease
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Subscribe To Our Newsletter & Stay Updated
